Clinical experience of laboratory follow-up with noninvasive prenatal testing using cell-free DNA and positive microdeletion results in 349 cases.

Autor: Schwartz S; Cytogenetics Laboratory, Laboratory Corporation of America® Holdings, Research Triangle Park, NC, 27709, USA., Kohan M; Integrated Genetics, LabCorp Specialty Testing Group, 655 Huntington Drive, Monrovia, CA, 91016, USA., Pasion R; Cytogenetics Laboratory, Laboratory Corporation of America® Holdings, Research Triangle Park, NC, 27709, USA., Papenhausen PR; Cytogenetics Laboratory, Laboratory Corporation of America® Holdings, Research Triangle Park, NC, 27709, USA., Platt LD; David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.; Center for Fetal Medicine and Women's Ultrasound, Los Angeles, CA, USA.
Jazyk: angličtina
Zdroj: Prenatal diagnosis [Prenat Diagn] 2018 Feb; Vol. 38 (3), pp. 210-218. Date of Electronic Publication: 2018 Feb 26.
DOI: 10.1002/pd.5217
Abstrakt: Objective: Screening via noninvasive prenatal testing (NIPT) involving the analysis of cell-free DNA (cfDNA) from plasma has become readily available to screen for chromosomal and DNA aberrations through maternal blood. This report reviews a laboratory's experience with follow-up of positive NIPT screens for microdeletions.
Methods: Patients that were screened positive by NIPT for a microdeletion involving 1p, 4p, 5p, 15q, or 22q who underwent diagnostic studies by either chorionic villus sampling or amniocentesis were evaluated.
Results: The overall positive predictive value for 349 patients was 9.2%. When a microdeletion was confirmed, 39.3% of the cases had additional abnormal microarray findings. Unrelated abnormal microarray findings were detected in 11.8% of the patients in whom the screen positive microdeletion was not confirmed. Stretches of homozygosity in the microdeletion were frequently associated with a false positive cfDNA microdeletion result.
Conclusions: Overall, this report reveals that while cfDNA analysis will screen for microdeletions, the positive predictive value is low; in our series it is 9.2%. Therefore, the patient should be counseled accordingly. Confirmatory diagnostic microarray studies are imperative because of the high percentage of false positives and the frequent additional abnormalities not delineated by cfDNA analysis.
(© 2018 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz: